# AZD5305 hADME in Patients With Advanced Solid Malignancies

> **NCT06713369** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 8 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumor

## Interventions

- **DRUG:** Saruparib (AZD5305)
- **DRUG:** [14C]-AZD5305 microtracer
- **DRUG:** [14C]-AZD5305 (therapeutic dose)

## Key facts

- **NCT ID:** NCT06713369
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-02
- **Primary completion:** 2026-10-02
- **Final completion:** 2026-10-02
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06713369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06713369, "AZD5305 hADME in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06713369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*